000100.KS
Yuhan Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 81,400.00
+0.12%Year over year
Reported trailing growth
- Revenue
- +5.4%
- EBITDA
- -21.3%
- EBIT
- +35.5%
- EPS
- +153.2%
- Free cash flow
- +120.4%
- Operating cash flow
- +161.3%
Forward estimates
Based on analyst estimates
- Revenue
- +4.2%
- EBITDA
- +15.1%
- EPS
- -44.9%
Three-year CAGR
- Revenue
- +7.2%
- EBITDA
- +30.7%
- EBIT
- +50.8%
- Net income
- +26.8%
- EPS
- +29.1%
- Free cash flow
- +95.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026